Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Research Use Limitation Used solely for in vitro experiments Not permitted for clinical trials involving humans Not permitted for human or veterinary administration Not permitted for investigational human use Independent third-party laboratory verification by Liquilabs s.r.o
The study was described as the first to demonstrate that FOXO4-DRI activates the p53/BCL-2/Caspase-3 pathway specifically in senescent endothelial cells
Limited data indicates that while compounds like SS-31 serve vital roles in narrow, orphan disease states, their benefits do not translate to healthy individuals
The meeting could open a clearer legal path for pharmacies to compound these substances for patient-specific prescriptions
10.3390/ijms23136923 57 LeeM.ChoT.JantaratnotaiN.WangY
This approach ensures high local concentrations where healing is needed most
US$ 21.60
US$ 25.72
US$ 25.23
US$ 24.35
US$ 20.51
US$ 26.78
